Jeffrey W. Albers - Net Worth and Insider Trading

Jeffrey W. Albers Net Worth

The estimated net worth of Jeffrey W. Albers is at least $14 Million dollars as of 2024-10-05. Jeffrey W. Albers is the Director of Blueprint Medicines Corp and owns about 157,557 shares of Blueprint Medicines Corp (BPMC) stock worth over $14 Million. Jeffrey W. Albers is also the Director of Kymera Therapeutics Inc and owns about 0 shares of Kymera Therapeutics Inc (KYMR) stock worth over $0. Details can be seen in Jeffrey W. Albers's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jeffrey W. Albers has not made any transactions after 2024-09-09 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Jeffrey W. Albers

To

Jeffrey W. Albers Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jeffrey W. Albers owns 3 companies in total, including Blueprint Medicines Corp (BPMC) , Kymera Therapeutics Inc (KYMR) , and Magenta Therapeutics Inc (MGTA) .

Click here to see the complete history of Jeffrey W. Albers’s form 4 insider trades.

Insider Ownership Summary of Jeffrey W. Albers

Ticker Comapny Transaction Date Type of Owner
BPMC Blueprint Medicines Corp 2024-09-09 director & CEO & President
KYMR Kymera Therapeutics Inc 2024-08-26 director
MGTA Magenta Therapeutics Inc 2018-06-20 director

Jeffrey W. Albers Latest Holdings Summary

Jeffrey W. Albers currently owns a total of 2 stocks. Among these stocks, Jeffrey W. Albers owns 157,557 shares of Blueprint Medicines Corp (BPMC) as of September 9, 2024, with a value of $14 Million and a weighting of 100%. Jeffrey W. Albers also owns 0 shares of Kymera Therapeutics Inc (KYMR) as of August 26, 2024, with a value of $0 and a weighting of 0%.

Latest Holdings of Jeffrey W. Albers

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BPMC Blueprint Medicines Corp 2024-09-09 157,557 88.58 13,956,399
KYMR Kymera Therapeutics Inc 2024-08-26 0 43.06 0

Holding Weightings of Jeffrey W. Albers


Jeffrey W. Albers Form 4 Trading Tracker

According to the SEC Form 4 filings, Jeffrey W. Albers has made a total of 29 transactions in Blueprint Medicines Corp (BPMC) over the past 5 years, including 0 buys and 29 sells. The most-recent trade in Blueprint Medicines Corp is the sale of 19,702 shares on September 9, 2024, which brought Jeffrey W. Albers around $2 Million.

According to the SEC Form 4 filings, Jeffrey W. Albers has made a total of 3 transactions in Kymera Therapeutics Inc (KYMR) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Kymera Therapeutics Inc is the sale of 5,000 shares on August 26, 2024, which brought Jeffrey W. Albers around $245,500.

Insider Trading History of Jeffrey W. Albers

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jeffrey W. Albers Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Jeffrey W. Albers Ownership Network

Ownership Network List of Jeffrey W. Albers

No Data

Ownership Network Relation of Jeffrey W. Albers

Insider Network Chart

Jeffrey W. Albers Owned Company Details

What does Blueprint Medicines Corp do?

Who are the key executives at Blueprint Medicines Corp?

Jeffrey W. Albers is the director & CEO & President of Blueprint Medicines Corp. Other key executives at Blueprint Medicines Corp include President & R and D Fouad Namouni , Principal FAO Michael Landsittel , and Chief Commercial Officer Philina Lee .

Blueprint Medicines Corp (BPMC) Insider Trades Summary

Over the past 18 months, Jeffrey W. Albers made 10 insider transaction in Blueprint Medicines Corp (BPMC) with a net sale of 165,808. Other recent insider transactions involving Blueprint Medicines Corp (BPMC) include a net sale of 38,146 shares made by Michael Landsittel , a net sale of 14,415 shares made by Ariel Hurley , and a net sale of 9,342 shares made by Christopher K. Murray .

In summary, during the past 3 months, insiders sold 69,657 shares of Blueprint Medicines Corp (BPMC) in total and bought 0 shares, with a net sale of 69,657 shares. During the past 18 months, 464,866 shares of Blueprint Medicines Corp (BPMC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 464,866 shares.

Blueprint Medicines Corp (BPMC)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Blueprint Medicines Corp Insider Transactions

No Available Data

Jeffrey W. Albers Mailing Address

Above is the net worth, insider trading, and ownership report for Jeffrey W. Albers. You might contact Jeffrey W. Albers via mailing address: Blueprint Medicines Corp., 215 First Street, Suite 340/350, Cambridge Ma 02142.

Discussions on Jeffrey W. Albers

No discussions yet.